Rajesh Singh, MD
Psychiatry · Sioux Falls, SDNPI 1710933684
Payments from drug & device makers
Across 730 payments — averaging $538.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$123K
- E.r. Squibb & Sons, L.L.C.$96K
- Alkermes, Inc.$96K
- Sunovion Pharmaceuticals Inc.$62K
- Eisai Inc.$9K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- plus $4K from 25 others
What the payments were for
- Consulting fees$25,0556%
- Speaking & faculty fees$326,16083%
- Travel & lodging$28,0757%
- Food & beverage$12,8723%
- Education$7970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 151 | $122,608 |
| E.r. Squibb & Sons, L.L.C. | 112 | $96,334 |
| Alkermes, Inc. | 111 | $96,073 |
| Sunovion Pharmaceuticals Inc. | 81 | $61,741 |
| Eisai Inc. | 11 | $9,230 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $3,009 |
| Otsuka America Pharmaceutical, Inc. | 59 | $900 |
| Supernus Pharmaceuticals, Inc. | 40 | $609 |
| Tris Pharma Inc | 11 | $383 |
| Lundbeck LLC | 22 | $332 |
| Johnson & Johnson | 16 | $283 |
| Jazz Pharmaceuticals Inc. | 10 | $163 |
| Vertical Pharmaceuticals, LLC | 12 | $134 |
| Shire North American Group Inc | 11 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $120 |
| Acadia Pharmaceuticals Inc | 6 | $108 |
| Vanda Pharmaceuticals Inc. | 4 | $105 |
| Corium, LLC | 9 | $104 |
| Merck | 6 | $82 |
| Ironshore Pharmaceuticals Inc. | 6 | $77 |
| Avanir Pharmaceuticals, Inc. | 5 | $73 |
| Neurocrine Biosciences, Inc. | 4 | $69 |
| Harmony Biosciences LLC | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Neuronetics, Inc. | 1 | $41 |
| Idorsia Pharmaceuticals US Inc | 3 | $40 |
| AbbVie | 2 | $32 |
| Almatica Pharma LLC | 2 | $28 |
| Bausch Health US, LLC | 1 | $23 |
| Biogen | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$377,184
- COBENFY$76,916
- UZEDY$67,232
- LATUDA$60,462
- Austedo XR$29,322
- AUSTEDO$23,754
- Leqembi$5,580
- Dayvigo$3,600
- CAPLYTA$2,750
- QELBREE$264
- Quillichew ER$243
- Dyanavel XR$243
- Quillivant$243
How this compares
$392,959 in reported general payments places this provider in the 95th percentile of 79 psychiatry providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 67 | $224,318 |
| IngrezzaValbenazine Tosylate | 12 | $93,380 |
| RexultiBrexpiprazole | 43 | $67,655 |
| VraylarCariprazine Hcl | 48 | $65,722 |
| NuedextaDextromethorphan Hbr/Quinidine | 39 | $61,656 |
| LybalviOlanzapine/Samidorphan Malate | 29 | $44,758 |
| TrintellixVortioxetine Hydrobromide | 89 | $43,938 |
| UzedyRisperidone | 14 | $38,737 |
| CaplytaLumateperone Tosylate | 17 | $25,965 |
| Clozapine | 503 | $23,675 |
| Methylphenidate ErMethylphenidate Hcl | 78 | $20,193 |
| Aripiprazole | 479 | $19,704 |
| BelsomraSuvorexant | 42 | $18,121 |
| Lurasidone Hcl | 39 | $17,887 |
| VyvanseLisdexamfetamine Dimesylate | 43 | $16,890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $283 | $237,83878 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $69 | $93,38012 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $900 | $67,65543 claims |
| AbbVieVraylar | $32 | $65,72248 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $73 | $61,65639 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $120 | $60,828132 claims |
| Alkermes, Inc.Lybalvi | $96,073 | $44,75829 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $122,608 | $38,73714 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $3,009 | $25,96517 claims |
| MerckBelsomra | $82 | $18,12142 claims |
| Eisai Inc.Dayvigo | $9,230 | $4,55815 claims |
| Almatica Pharma LLCSertraline Hcl | $28 | $3,297377 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 psychiatry providers in South Dakota.
Other psychiatry in Sioux Falls
- James ChiuSioux Falls$1.7M
- Hari KannanSioux Falls$913K
- Anthony VacaSioux Falls$15K
- Mackenzie MertzSioux Falls$4K
- Georgiana NussSioux Falls$4K
- Sandra Peynado RojasSioux Falls$3K
- David ErmerSioux Falls$3K
- Clay PavlisSioux Falls$2K
- William FullerSioux Falls$2K
- Xiaofan LiSioux Falls$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.